Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback. Today, a brief rundown of news from the Food and Drug Administration, as well as updates from Tome Biosciences, Sky Bioscience and Ambrosia Biosciences that you may have missed.The Food and Drug Administration will convene a panel of expert advisers on Sept. 26 to review use of Bristol Myers Squibbs Opdivo and Merck & Co.s Keytruda in gastrointestinal cancer. The advisory committee will be tasked with evaluating PD-L1 expression as a predictive biomarker of the drugs effectiveness in this setting, for which both are approved broadly. Data now suggest PD-L1 expression is important, the FDA said, but trials of the drugs measured expression differently. The FDA is seeking advice on how to judge this data and whether use of the immunotherapies should be restricted based on PD-L1 levels. Jonathan GardnerTome Biosciences, a buzzy genetic medicine startup, is scaling back operations and exploring strategic options, CEO Rahul Kakkar confirmed in an emailed statement to BioPharma Dive. Despite our clear scientific progress, investor sentiment has shifted dramatically across the gene editing space, particularly for preclinical companies, Kakkar said. The company, which in December had revealed it raised $213 million in venture funding, is in ongoing confidential conversations with multiple parties, he added. On Thursday, Stat reported Tome was struggling to raise funds and, according to one source that spoke to the publication, could wind down altogether. Ned PagliaruloPrescriptions for RSV shots from GSK and Pfizer have begun to tick higher over the past two weeks, although overall levels remain low ahead of the traditional fall vaccination season. Analysts are closely watching prescription trends as last year the vaccines brought in significant revenue for their makers. Moderna, which earlier this year won U.S. approval for a rival shot, is expected to gain only a small share of the market, according to an Aug. 23 note from Jefferies analyst Michael Yee. Ned PagliaruloSkye Bioscience has begun screening patients for a Phase 2 trial of an experimental obesity drug that works by blocking a cannabinoid receptor. The antibody drug, called nimacimab, will be tested alone and in combination with Novo Nordisks Wegovy over 26 weeks of treatment. Skye believes blocking cannabinoid signaling will promote energy expenditures and modulate hunger. An earlier, small molecule drug that blocked cannabinoid receptors, called rimonabant, gained approval in Europe under the name Acomplia but was later withdrawn because of psychiatric side effects. Skye says nimacimab is less active in the brain, which it claims will limit those side effects. Jonathan GardnerNew biotech startup Ambrosia Biosciences has raised $16 million to discover and develop oral drugs for obesity. Announced Tuesday, the Series A financing round was led by BVF Partners and Boulder Ventures. Ambrosia was formed by former employees of Array BioPharma, which Pfizer acquired in 2019. The pharmaceutical giant recently shut down an Array research and development facility in Boulder, Colorado, giving Ambrosia an opportunity to reassemble the team in a new company. Ned Pagliarulo '